[go: up one dir, main page]

LV10956A - Dimetilbenzofuranu un dimetilbenzopiranu ka 5-HT3 antagonistu izmantosana - Google Patents

Dimetilbenzofuranu un dimetilbenzopiranu ka 5-HT3 antagonistu izmantosana

Info

Publication number
LV10956A
LV10956A LV950184A LV950184A LV10956A LV 10956 A LV10956 A LV 10956A LV 950184 A LV950184 A LV 950184A LV 950184 A LV950184 A LV 950184A LV 10956 A LV10956 A LV 10956A
Authority
LV
Latvia
Prior art keywords
pct
date jun
represents hydrogen
sec
formula
Prior art date
Application number
LV950184A
Other languages
English (en)
Other versions
LV10956B (en
Inventor
Georges Henri Paul Van Daele
Jean-Paul Rene Marie A Bosmans
Willy Joannes Carolu Laerhoven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LV10956A publication Critical patent/LV10956A/lv
Publication of LV10956B publication Critical patent/LV10956B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LVP-95-184A 1992-11-20 1995-06-20 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists LV10956B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (2)

Publication Number Publication Date
LV10956A true LV10956A (lv) 1995-12-20
LV10956B LV10956B (en) 1996-10-20

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-184A LV10956B (en) 1992-11-20 1995-06-20 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Country Status (31)

Country Link
US (2) US5674868A (lv)
EP (1) EP0669919B1 (lv)
JP (1) JP2830952B2 (lv)
KR (1) KR0166661B1 (lv)
AT (1) ATE176232T1 (lv)
AU (1) AU680640B2 (lv)
BG (1) BG62489B1 (lv)
BR (1) BR9307477A (lv)
CA (1) CA2149044C (lv)
CZ (1) CZ287262B6 (lv)
DE (1) DE69323322T2 (lv)
DK (1) DK0669919T3 (lv)
ES (1) ES2129615T3 (lv)
FI (1) FI952458A (lv)
GR (1) GR3029831T3 (lv)
HU (2) HUT72740A (lv)
IL (3) IL119273A (lv)
LV (1) LV10956B (lv)
MX (1) MX9307257A (lv)
NO (2) NO307690B1 (lv)
NZ (1) NZ257854A (lv)
OA (1) OA10158A (lv)
PL (1) PL176051B1 (lv)
RO (1) RO115160B1 (lv)
RU (1) RU2116072C1 (lv)
SG (1) SG47488A1 (lv)
SK (1) SK282378B6 (lv)
TW (1) TW294595B (lv)
UA (1) UA49792C2 (lv)
WO (1) WO1994012494A1 (lv)
ZA (1) ZA938676B (lv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
CA2286076C (en) 1997-04-18 2006-12-12 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
JP3529102B2 (ja) * 1997-07-11 2004-05-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ 5−ht3および5−ht4介在性障害に有用な(+)−ノルシサプリド
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
SG150533A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
CN1882549B (zh) 2003-11-20 2011-02-23 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
US7803795B2 (en) 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
AU2005259190B2 (en) 2004-06-30 2011-05-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as PARP inhibitors
KR101286969B1 (ko) 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Parp 저해제로서의 퀴나졸리논 유도체
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
CA2716088C (en) 2008-03-27 2017-03-07 Eddy Jean Edgard Freyne Quinazolinone derivatives as tubulin polymerization inhibitors
MX2010010406A (es) 2008-03-27 2010-10-25 Janssen Pharmaceutica Nv Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
ATE176232T1 (de) 1999-02-15
BR9307477A (pt) 1999-06-29
IL119273A0 (en) 1996-12-05
RU95113434A (ru) 1997-03-10
WO1994012494A1 (en) 1994-06-09
US5674868A (en) 1997-10-07
HUT72740A (en) 1996-05-28
PL176051B1 (pl) 1999-03-31
PL309045A1 (en) 1995-09-18
DE69323322T2 (de) 1999-09-09
UA49792C2 (uk) 2002-10-15
FI952458A0 (fi) 1995-05-19
KR0166661B1 (ko) 1999-01-15
EP0669919A1 (en) 1995-09-06
SK282378B6 (sk) 2002-01-07
CA2149044A1 (en) 1994-06-09
HU9501476D0 (en) 1995-07-28
NO308530B1 (no) 2000-09-25
MX9307257A (es) 1994-05-31
OA10158A (en) 1996-12-18
DE69323322D1 (de) 1999-03-11
NO951980D0 (no) 1995-05-19
IL107654A (en) 1998-01-04
ZA938676B (en) 1995-05-19
SK67595A3 (en) 1995-11-08
IL119273A (en) 2000-07-16
NO951980L (no) 1995-05-19
JPH08505840A (ja) 1996-06-25
GR3029831T3 (en) 1999-06-30
CA2149044C (en) 2007-04-03
NO307690B1 (no) 2000-05-15
BG99593A (en) 1995-12-29
CZ125895A3 (en) 1995-10-18
FI952458A (fi) 1995-05-19
LV10956B (en) 1996-10-20
AU5465994A (en) 1994-06-22
RU2116072C1 (ru) 1998-07-27
TW294595B (lv) 1997-01-01
RO115160B1 (ro) 1999-11-30
CZ287262B6 (en) 2000-10-11
BG62489B1 (bg) 1999-12-30
IL107654A0 (en) 1994-02-27
US5863923A (en) 1999-01-26
NO995762D0 (no) 1999-11-24
DK0669919T3 (da) 1999-09-13
SG47488A1 (en) 1998-04-17
JP2830952B2 (ja) 1998-12-02
AU680640B2 (en) 1997-08-07
HU211546A9 (en) 1995-12-28
EP0669919B1 (en) 1999-01-27
NZ257854A (en) 1997-04-24
NO995762L (no) 1995-05-19
ES2129615T3 (es) 1999-06-16

Similar Documents

Publication Publication Date Title
LV10956A (lv) Dimetilbenzofuranu un dimetilbenzopiranu ka 5-HT3 antagonistu izmantosana
GB9524157D0 (en) Therapeutic agents
SE0104332D0 (sv) Therapeutic agents
AU6073596A (en) Intermediates useful in the preparation of 5-HT4 receptor antagonists
GR3034769T3 (en) Triazole antifungal agents.
FI943931A (fi) Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
LV11545A (lv) Pozitivas inotropas un lusitropas iedarbibas pirolohinolinona atvasinajumi